Loading clinical trials...
Loading clinical trials...
A Phase 2a, Observer-Blind, Randomized, Controlled, Age-De-Escalation, Single-center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella (iNTS) Disease and Typhoid Fever, Including Dose and Schedule Finding in Infants, in Africa
Conditions
Interventions
Low dose of iNTS-TCV
Full dose of iNTS-TCV
+4 more
Locations
1
The Gambia
GSK Investigational Site
Banjul, The Gambia
Start Date
April 1, 2026
Primary Completion Date
April 27, 2028
Completion Date
April 27, 2028
Last Updated
April 20, 2026
NCT05480800
NCT02689193
NCT01608815
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions